Panagora Asset Management’s ImmunityBio IBRX Stock Holding History

Panagora Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,279	Closed	-$146K	–	1242
2024 Q1	$146K	Buy	+27,279	New	+$124K	﹤0.01%	1171
2021 Q2	–	Sell	-27,544	Closed	-$654K	–	2856
2021 Q1	$654K	Sell	27,544 -26,195	-49%	-$679K	﹤0.01%	1210
2020 Q4	$716K	Buy	53,739 +408	+0.8%	+$3.92K	﹤0.01%	1097
2020 Q3	$370K	Hold	53,331	–	–	﹤0.01%	1278
2020 Q2	$655K	Buy	+53,331	New	+$301K	﹤0.01%	1098
2016 Q1	–	Sell	-46,363	Closed	-$803K	–	2313
2015 Q4	$803K	Buy	+46,363	New	+$688K	﹤0.01%	1147

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Panagora Asset Management's IBRX Position: Q2 2024 in Review

Panagora Asset Management sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 27,279 shares — an estimated $146K sold.

Panagora Asset Management first reported a position in IBRX in Q4 2015 and held it in 6 quarters. The position peaked at $803K in Q4 2015. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

Panagora Asset Management reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
Panagora Asset Management sold 27,279 ImmunityBio shares in Q2 2024, an estimated $146K.
Panagora Asset Management first reported a position in ImmunityBio in Q4 2015 and held it in 6 quarters.
Panagora Asset Management's ImmunityBio position peaked at $803K in Q4 2015.
193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Panagora Asset Management's 13F filing for Q2 2024, filed 29 Jul 2024.